FTC To Focus On In-House Challenge Of Illumina Deal
The Federal Trade Commission said Thursday enforcers plan to drop their bid for a court order to pause Illumina's planned $8 billion purchase of cancer testing company Grail and will instead...To view the full article, register now.
Already a subscriber? Click here to view full article